Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Research advances on DKK1 in head and neck squamous cell carcinoma: Linking molecular mechanisms to clinical applications (Review).

Oncology reports·2026
Same author

The Dickkopf Protein Family in Non-Neoplastic Disorders: Emerging Roles and Therapeutic Targeting.

Aging and disease·2026
Same author

Design and Evaluation of <sup>68</sup>Ga-Labeled Peptide-Based PET Probes for Noninvasive Imaging of ROR1 Expression in Tumor Models.

Journal of medicinal chemistry·2026
Same author

Recent advances in Epstein-Barr virus vaccines development from mechanistic exploration to clinical translation.

NPJ vaccines·2026
Same author

Theranostic Study of PSMA-Targeted Radioligands Modified with Enhancer SNAC.

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Apr 23, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K

Development of Lipid-Engineered PSMA-Targeted Radioligands with Quinoline Scaffold.

Tao Zhang1, Zhexin He1, Yaoxuan Wang1

  • 1State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Fujian Engineering Research Center of Molecular Theranostic Technology, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, Fujian 361102, China.

Journal of Medicinal Chemistry
|April 22, 2026
PubMed
Summary

Researchers improved prostate cancer imaging and therapy by designing new prostate-specific membrane antigen (PSMA) ligands. These modified ligands show enhanced tumor uptake and retention for better diagnostic and therapeutic outcomes in prostate cancer (PCa).

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

6.2K

Related Experiment Videos

Last Updated: Apr 23, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

6.2K

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • Prostate-specific membrane antigen (PSMA) is a key biomarker and therapeutic target in prostate cancer (PCa).
  • Current PSMA-targeted small-molecule probes often exhibit insufficient tumor uptake and retention, limiting their clinical utility.
  • Developing novel PSMA ligands with improved pharmacokinetic properties is crucial for advanced PCa diagnostics and therapeutics.

Purpose of the Study:

  • To design and synthesize novel PSMA ligands with enhanced tumor accumulation and retention for prostate cancer imaging and therapy.
  • To evaluate the efficacy of lipidation and fatty acid modification strategies in improving PSMA-targeted radioligand performance.
  • To assess the diagnostic and therapeutic potential of new 68Ga- and 177Lu-labeled PSMA ligands in preclinical models.

Main Methods:

  • Rational design and synthesis of PSMA ligands incorporating lipid chains and fatty acids.
  • Radiolabeling of selected ligands with Gallium-68 (68Ga) for PET imaging and Lutetium-177 (177Lu) for therapy.
  • In vitro cellular studies and molecular docking to confirm PSMA specificity and binding affinity.
  • In vivo evaluation using PET imaging and biodistribution studies in a PC-3 PIP xenograft mouse model.

Main Results:

  • Cellular studies and molecular docking confirmed PSMA specificity and binding properties of the synthesized ligands.
  • PET imaging in a PC-3 PIP xenograft model revealed significant tumor accumulation and retention for 68Ga-labeled ligands [68Ga]Ga-PDA2-C6 and [68Ga]Ga-PDA1-1.
  • These ligands demonstrated improved tumor-to-nontarget (T/NT) ratios compared to other evaluated probes.
  • Biodistribution studies confirmed pronounced tumor retention of 177Lu-labeled counterparts, [177Lu]Lu-PDA2-C6 and [177Lu]Lu-PDA1-1.
  • Low kidney retention was observed for the developed radioligands.

Conclusions:

  • Conjugating PSMA ligands with tailored lipid chains and fatty acids effectively enhances tumor uptake and retention.
  • The developed PSMA-targeted radioligands, PDA2-C6 and PDA1-1, show significant promise for improved prostate cancer diagnosis and therapy.
  • This strategy offers a viable approach to overcome limitations of existing PSMA-targeted agents, maintaining low off-target organ accumulation.